A trillion-dollar market cap, the point at which the combined market value of a company's shares tops $1 trillion, is a threshold many investors read as a ceiling. Eli Lilly (NYSE: LLY) has just crossed it, trading at $1,123.98 with a market capitalization of $1.002 trillion. Analysts at 24/7 Wall St. rate the stock a buy, with a 12-month price target of $1,220.42 and a stated confidence level of 90%.
The short version: shares are up 50.72% over the past year and down 8.61% over the past month, sitting below the 52-week high of $1,292.65.
What the revenue numbers show
Mounjaro and Zepbound, Eli Lilly's diabetes and weight-loss drugs, have been the revenue engine. Second-quarter 2026 revenue reached $22.974 billion, up 47.67% year over year. Mounjaro alone posted $9.94 billion, a 91% increase from a year earlier. EPS (earnings per share, a company's profit divided by shares outstanding) came in at $8.38, beating Wall Street's consensus by 27.27%, the fourth consecutive quarter Lilly has cleared the bar. Management raised full-year 2026 revenue guidance to between $85 billion and $87 billion.
For context on valuation, Novo Nordisk (NYSE: NVO), the primary competitor in the diabetes and weight-loss drug market, reported quarterly revenue growth of just 2.1% and trades at a forward price-to-earnings ratio of 14. Lilly trades at 24 times forward earnings. Merck (NYSE: MRK), a broader pharmaceutical comparison, carries a forward P/E of 16 but saw quarterly earnings shrink 19.3% year over year.
The bull and bear cases
The bull path, per 24/7 Wall St.'s model, takes LLY to $1,381.62, a 22.92% gain. The primary catalyst is retatrutide, a triple-agonist, meaning a compound designed to activate three distinct biological targets at once. Management said Phase 3 trials showed unprecedented efficacy, with a BLA (biologics license application, the formal regulatory filing that must clear review before a drug can go to market) planned for Q1 2027. Foundayo, an oral weight-loss pill with no food or water restrictions, has reached 36,000 prescribers. A Medicare access program extends coverage to 20 million eligible Americans at $50 per month. Lilly holds 55% of the international incretin drug market, and China revenue grew 93% in constant currency during the quarter.
The bear case puts shares at $1,045.34, a 7% decline. Realized drug prices fell 13% in the second quarter. The incretin franchise, drugs that target gut hormones to regulate blood sugar and appetite, generated roughly $14.87 billion of the quarter's revenue. That concentration is what 24/7 Wall St. flags as the main structural risk. IPR&D charges of $2.78 billion weighed on reported earnings; the analysts note those charges reflect pipeline acquisitions including Orna, Kelonia, Ajax, and Centessa.
The 24/7 Wall St. note frames retatrutide's Q1 2027 BLA filing as the deciding variable. The analysts say that if realized-price declines accelerate past 13% in coming quarters, the buy case does not hold.